30 Mar, 2023 Results on Discovery and Nonclinical Development of ALN-APP, Presented at the AD/PD™ 2023 Advances in Science & Therapy Congress
We presented non-clinical results on ALN-APP*, our investigational RNAi therapeutic for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy at AD/PD 2023 Advances in Science & Therapy International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, held on March 28-April 1 in Gothenburg, Sweden.
Brown, et al. – Discovery and Nonclinical Development of ALN-APP, an Investigational RNAi Therapeutic
*The ALN-APP clinical program is being conducted as a partnership between Alnylam Pharmaceuticals and Regeneron Pharmaceuticals, Inc.